

REMARKS


This Amendment is submitted along with the Issue Fee Transmittal form PTOL-85 in response to the Supplemental Notice of Allowability and Interview Summary mailed August 23, 2004 in which the Examiner in the Interview Summary of a July 23rd interview indicated that since the Notice of Allowability mailed February 4, 2004 had not been received by Applicants, the time period for response to the February 4, 2004 Notice of Allowability would be reset to begin with the mailing of the Interview Summary and Supplemental Notice of Allowability on August 23, 2004. Accordingly, Applicants submit that this Amendment and the accompanying Issue Fee Transmittal form PTOL-85 are timely submitted within 3 months from the August 23, 2004 mailing date of Interview Summary and Supplemental Notice of Allowability.

The amendment to the specification to insert the brief description of Figure 1 finds support in Example 1 of the application and in particular, at page 8, line 16 of the application. Accordingly, no new matter is added by this amendment to the specification.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: November 23, 2004


Richard W. Bork, Reg. No. 36,459
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

Use the following customer number for all correspondence regarding this application.

23650

PATENT TRADEMARK OFFICE